Diabetes

The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.

Results are promising, particularly because they represent the second clinical trial of a GLP-1 receptor agonist showing potential benefits for PD motor symptoms

The analysis assessed the feasibility of autologous transplantation of chemically-induced pluripotent stem cell-derived islets for type 1 diabetes.

As of now, data suggest minimal risk of drug interactions between oral contraceptives and injectable semaglutide.

The weight loss drug continues to show promise in treating a variety of other conditions.

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

Empathy is being left outside the exam room door.

Three of the largest pharmacy benefit managers ––Express Scripts, Optum, and Caremark––are listed in the suit.

Eversense 365 (Senseonics) is the first long-lasting continuous glucose monitoring (CGM) system, which includes a 365-day sensor and only 1 insertion on Day 1 of every year.

Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.

Pharmacists should be aware of these digital therapeutics, which are often used as an adjunct to medication, to better understand the treatment outcomes.

Previously, the device was indicated for the management of type 1 diabetes in patients aged 2 years and older.

Clinical improvements for patients with diabetes seen in a collaboration between the University of North Carolina and Blue Cross and Blue Shield of North Carolina.

For adults receiving the 15 mg dose, tirzepatide sustained weight loss with an average reduction of 22.9% in body weight compared with 2.1% for the placebo.

In an interview with Pharmacy Times, Jasmine Perry describes her idea of an effective health care delivery model and why research can have a huge impact at the policy level.

In an interview with Pharmacy Times, Jon Easter discusses the need for pharmacy to align as a profession to achieve policy and research goals.

Jasmine Perry discusses the More Than a Script program in an interview with Pharmacy Times.

Glucagon-like peptide-1 receptor agonists and sodium-glucose contransporter-2 inhibitors have been added as first-line therapy recommendation for type 2 diabetes, the first since metformin

Jon Easter talks about community pharmacy's role in propelling diabetes innovation and optimizing patient care.

Many patients are unaware of wound complication, so it is valuable for pharmacists to communicate prevention methods with all patients with diabetes.

The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.

The system is an outpatient procedure that resurfaces the mucosal lining, making it easier for the body to maintain healthy metabolism and blood glucose levels.

The presence of glutamic acid decarboxylase antibodies in intravenous immunoglobulin can lead to a misdiagnosis of type 1 diabetes mellitus if a false-positive result is garnered.

Kristian Hurley, senior vice president of Programs, Advocacy, and Health Equity at Beyond Type 1, discussed the importance of proactive screening for patients with signs of type 1 diabetes (T1D).

Because T1D is not necessarily caused by genetics, educating patients about the signs and helping them get tested early is crucial.

A 5:2 intermittent fasting plan combined with meal replacement had better positive outcomes compared with metformin and empagliflozin.

Use of semaglutide injections may be linked to an increased risk of blindness in patients with diabetes.

The FDA has issued a statement on suicidal thoughts or actions and has launched evaluations for that signal as well as alopecia and aspiration.

When used correctly, weight-loss medications, such as glucagon-like peptide-1 (GLP-1) medications, can be a tool to help reduce costs and provide clinical results.